‘Research has identified that inflammation in the brain is a key driver of the disease in the phase before the debilitating motor symptoms begin to appear.This is known as the prodromal period, and Macquarie University Professor of Cognitive Neurology Simon Lewis says that treatment at this point might be the best opportunity to defeat Parkinson’s.’
The phase 2 clinical trial to test SNT-4728, as a potential neuroprotective treatment to prevent Parkinson’s disease progression in patients with idiopathic REM sleep behavior disorder is due to conclude 31/1/2025 with results to follow This isn’t too far away!
This could be a game changer for the treatment of Parkinson’s. I have my fingers crossed for patients and Syntara. Not long to go!
SNT Price at posting:
8.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)